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Abstract Most studies of HIV latency focus on the peripheral
populationof restingmemoryTcells,but thebrainalsocontainsa
distinct reservoir ofHIV-infected cells inmicroglia, perivascular
macrophages, andastrocytes.StudyingHIVin thebrainhasbeen
challenging, since live cells are difficult to recover from autopsy
samples and primate models of SIV infection utilize viruses that
aremoremyeloid-tropic thanHIV due to the expression ofVpx.
Development of a realistic small animal model would greatly
advance studies of this important reservoir and permit definitive
studies ofHIV latency.When radiation or busulfan-conditioned,
immune-deficientNSGmiceare transplantedwithhumanhema-
topoietic stem cells, human cells from the bonemarrow enter the
brain and differentiate to express microglia-specific markers.
After infectionwith replicationcompetentHIV,viruswasdetect-
ed in these bone marrow-derived human microglia. Studies of
HIV latency in this model would be greatly enhanced by the
development of compounds that can selectively reverse HIV
latency in microglial cells. Our studies have identified members
of the CoREST repression complex as key regulators of HIV
latency in microglia in both rat and human microglial cell lines.
The monoamine oxidase (MAO) and potential CoREST inhibi-
tor, phenelzine, which is brain penetrant, was able to stimulate
HIV production in human microglial cell lines and human glial
cells recovered fromthebrainsofHIV-infectedhumanizedmice.
The humanized mice we have developed therefore show great
promise as a model system for the development of strategies
aimed at defining and reducing the CNS reservoir.
Keywords HIV latency . Epigenetic silencing . Humanized
mice .Microglial cell
Introduction
Reservoirs ofHIVpersist in the bodydespite antiretroviral therapy
(ART) (Barton et al. 2016; Boritz et al. 2016; Brew et al. 2015;
Katlamaet al. 2013).The reservoir includes populations of latently
infected cells that can be reactivated and restart an infection when
ART is interrupted. Most studies of HIV latency have focused on
thecentralmemoryTcellsfoundintheperipheralcirculation(Brew
et al. 2015; Siliciano and Siliciano 2013; Spivak and Planelles
2016); however, the CNS contains a significant reservoir that is
distinct from the Tcell compartment that has often been neglected
(reviewed in (Fois andBrew 2015; Hellmuth et al. 2015)).
Direct evidence for HIV infection of the brain has come from
autopsy samples (Desplats et al. 2013; Thompson et al. 2011),
with HIV DNA detected in astrocytes, perivascular macro-
phages, and microglia (Churchill et al. 2006; Thompson et al.
2011). Although astrocytes show infection rates up to 19%
(Churchill et al. 2009), they produce little to no infectious virus
(Gorry et al. 2003;Messam andMajor 2000), suggesting that the
source of persisting HIV in the CNS is instead the microglia or
perivascular macrophages. Primary human microglia can be
readily infected by HIV ex vivo (Garcia-Mesa et al. 2017;
Jordan et al. 1991), and recent studies have shown that they are
muchmore permissive to infection than macrophages from other
tissues (Cenker et al. 2017).
Persistence of HIV in the CNS may be facilitated by sub-
optimal drugpenetration across theblood-brainbarrier, although
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there is little evidence for a high level of ongoing active replica-
tion in the CNS in well-suppressed patients or the emergence of
drug-resistant strains (Bednar et al. 2015; Dahl et al. 2014;
Gianella et al. 2016; Schnell et al. 2011). Virus also rebounds in
theCNSafterARTinterruption, analogously to lymphoid tissues
(Gianella et al. 2016).We therefore favor thehypothesis thatHIV
persists in the CNS due primarily to the establishment of latent
HIV infections, especially in the microglial cell population,
which is highly permissive for HIV infection (Cenker et al.
2017). Curing HIVwill therefore require strategies that remove,
disable, or suppress all latent HIV reservoirs, including those
specific to the CNS (Brew et al. 2015; Fois and Brew 2015;
Garrido andMargolis 2015).
StudiesofHIVinfection in theCNSarechallenging, andhave
relied historically onpost-mortem samples or on cell linemodels
thatmaynot fully recapitulate invivo systems.Althoughprimate
SIV infection models have provided important insights about
CNS infection, (Zink et al. 1999), the presence of Vpx in SIV,
which counteracts the myeloid restriction factor SamHD1 and
leads to enhanced infection of perivascular macrophages and
microglial cells, means that some findings from the SIVmodels
maynot be translatable toHIV.There is therefore apressingneed
to developbetter animalmodels ofHIVinfection in theCNS that
not only support infection of relevant human cell types, such as
human perivascular macrophages and microglia, but also reca-
pitulate featuresof theHIV life cycle, including thedevelopment
of latency during ART.
Humanized mice are being explored as a readily accessible
model for HIV CNS infection (Honeycutt et al. 2015). Early
approaches included the direct injection of HIV-infected mono-
cyte-derived macrophages into the brains of immunodeficient
mice (Persidsky et al. 1996; Poluektova et al. 2002, 2004;
Potula et al. 2005; Tyor et al. 1993). Although this can result
in high levels of engraftment around the site of injection, the
mice only survived up to 4weeks post-injection, and the trauma
caused by the injection itself induced potentially confounding
levels of inflammation (Honeycutt et al. 2015). In contrast,
systemic injection of human HSC into immune-deficient
strains, such as NSGmice, creates humanizedmice that support
long-term engraftment of human cells in the blood and lym-
phoid tissues. Unfortunately, only low numbers of human cells
have been observed in the brains of these mice by histology and
qPCR (Honeycutt et al. 2016; Dash et al. 2011). When human-
ized mice are infected with HIV, p24+ cells can be detected in
the brain (Gorantla et al. 2010; Honeycutt et al. 2016), and
neuronal damage, inflammation, and increased mouse microg-
lia proliferation have been reported (Dash et al. 2011; Boska
et al. 2014; Gorantla et al. 2010), mimicking aspects of AIDS-
related dementia seen in untreated patients. Although some of
the human cells in humanized mouse brains have been reported
to express the microglia marker Iba1 (Asheuer et al. 2004),
none of the published studies have specifically demonstrated
HIV-infected human microglia.
Inthepresentstudy,wecharacterizedthehumancellspresentin
the brains of NSGmice transplanted with human HSC and iden-
tifiedhumancells expressingmarkersofmicroglia.Usingspecific
conditioning regimens, up to 10%of themicroglia in the brains of
these animals were of human origin and could be readily infected
by HIV in vivo. This is a critical first step to investigate whether
latency can develop in themicroglial cell population in vivo. Our
previous studies of immortalized human microglial cells have
shown that latency can readily develop in microglial cells due to
the imposition of epigenetic restrictions (Alvarez-Carbonell et al.
2017; Garcia-Mesa et al. 2017). In order to develop tools to study
latency in thehumanizedmousemodel,weused thesecellmodels
to identify compounds that can potently and selectively reverse
latency in microglial cells. Intriguingly, after isolation of the hu-
manmicroglialcellsfromthemice,viralreactivationwasachieved
using the monoamine oxidase (MAO) inhibitor phenelzine, sug-
gesting that a subset of these cells may harbor latent proviruses.
Results
Strategy for developing a humanized mouse model
to study HIV latency
Our strategy to repopulate the brains of immune-deficient NSG
mice with human microglial cells was based on prior studies
showing that depletion of CNS myeloid cells occurs following
treatmentwith radiation(EglitisandMezey1997),orbyexposure
of CD11b-HSVTK transgenic mice to intracerebroventricular
ganciclovir (GCV) (Varvel et al. 2012), allows repopulation of
such microglia-depleted brains by mouse peripheral monocytes.
In the studies of Varvel et al. (2012), GCV depletion allowed the
brains to become repopulated with bone marrow-derived mono-
cytes that expressed high levels of CD45 and CCR2 and, upon
entry into thebrain,expressedthesentinelmicroglialmarker Iba1.
Although the infiltrating monocytes were two times more
numerous and morphologically distinct from resident microglia,
they became uniformly distributed throughout the brain, and had
anoveralldistributionandbehavior thatwasremarkablysimilar to
that ofmicroglia. In addition,workbyAsheuer et al. (2004) dem-
onstrated that the repopulating cells could also be derived from
transplantedhumanbonemarrowcells.Adaptingandsimplifying
this method for use with HIV, we reasoned that NSG mice
reconstituted with human hematopoietic stem cells would also
contain cells that could differentiate into a microglial phenotype
in the brain and subsequently support infection byHIV.
Identification and quantification of human microglia
in humanized NSG mice
Humanized NSG mice were created by standard procedures
using total body irradiation to condition adult mice, followed
by transplantation with up to 106 human CD34+ HSC (Holt
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et al. 2010; Wang et al. 2015) (Fig. 1 a). At the same time, we
also evaluated an alternate conditioning regimen based on the
chemotherapeutic agent, busulfan, since this has been reported
to increase the frequency of donor HSC-derived microglia
present in the brains of mice undergoing transplantation with
mouse HSC (Wilkinson et al. 2013). The CD34+ cells used to
generate these mice were isolated from a single source to
eliminate human donor cell variation.
At 16-week post-transplantation, mice were euthanized,
perfused with PBS to deplete contaminating blood cells from
the brain, and the glial fraction was then isolated from brain
tissue using a Percoll gradient. This fraction was immuno-
stained for a human-specific marker (hCD45), as well as the
microglial markers CD11b and P2RY12 (Fig. 1b–e) (Bennett
et al. 2016; Butovsky et al. 2014). P2RY12 is a more specific
marker for microglia than CD11b, which is also expressed on
macrophages, but we observed that almost all the cells ex-
pressing either marker were both P2RY12+ and CD11b+. We
found both an increase in the overall frequency of human cells
in the brains of busulfan-conditioned mice compared to the
irradiated mice, and a corresponding increase in the frequency
of human cells in the total CD11b+ P2RY12+ fraction, which
includes both mouse and human microglia (Fig. 1e).
HIV infection of microglia in the brain of humanized mice
To determine whether the human microglia in the brains of
humanized mice could be infected by HIV in vivo, we chal-
lenged five humanized mice with an R5-tropic strain of HIV,
JRCSF-HA. This virus contains a surface expressed hemag-
glutinin (HA) epitope-tagged protein that can be used to iden-
tify productively infected cells by flow cytometry. Viremia
was monitored in the blood of all animals over 12 weeks
(Fig. 2a), at which point the mice were necropsied and the
glial cells isolated and stained for hCD45, CD11b, and HA.
We observed that 2–15% of the hCD45+ CD11b+ cells were
also positive for HA, indicating the presence of productively
HIV-infected microglia (Fig. 2b).
Fig. 1 Human microglia in the brains of humanized mice. a
Experimental scheme to create humanized mice using either irradiation
or busulfan conditioning. At necropsy, the total glial fraction was isolated
using a Percoll gradient, and the human cells andmicroglia in that fraction
identified by flow cytometry using indicated markers. b Representative
flow cytometry analysis of human microglia (hCD45+/CD11b+/
P2rY12+) in an irradiated mouse. c Representative flow cytometry plot
analysis of human microglia in a mouse conditioned with busulfan. d
Quantification of human microglia in n = 3 irradiated mice. e
Quantification of human microglia in n = 4 busulfan-conditioned mice.
f Comparison of levels of human cell (hCD45+) contribution in the glial
fraction, and the total microglial population, in irradiated versus busulfan-
conditioned mice
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Identification of selective inducers of HIV proviral latency
Although significant progress has been made in our under-
standing of the mechanisms promoting HIV latency in Tcells,
the mechanisms that could contribute to latency in microglia
are less well understood (Alvarez-Carbonell et al. 2017). To
identify genes involved inmaintaining HIV latency inmicrog-
lia, we performed a genome-wide shRNA library screen using
CHME-5/HIV cells. CHME-5/HIV cells are a rat microglial
cell line that contains a single integrated copy of a defective
reporter HIV genome, in which Nef has been replaced by a
short-lived GFP reporter (d2EGFP). The HIV genome is la-
tent, but can be reactivated to express GFP by agents such as
TNF-α or trichostatin A (Wires et al. 2012).
The shRNA screen used a genome-wide lentiviral library
from Cellecta, combined with systems biology classifications
of the hits, as previously described (Li et al. 2016; Nguyen
et al. 2017). Briefly, the CHME-5/HIV cells were transduced
with the shRNA library vectors, and GFP+ cells were selected
by cell sorting. The target genes of the shRNAs leading to
reactivation determined by sequencing (Li et al. 2016;
Nguyen et al. 2017). As summarized in Fig. 3a, members of
the CoREST repression complex, including HDAC2, CTBP1,
and CTBP2, were highly ranked Bhits^ in the screen. These
candidates were confirmed by specific shRNA-mediated
knockdown of the CoREST protein and its associated co-
factors in CHME-5/HIV cells.
To confirm the role of the CoREST repression complex in
maintainingHIVlatency inmicroglial cells,weusedour recently
developed model of HIV latency in human microglia cells
(Hμglia/HIV), clone HC69 (Alvarez-Carbonell et al. 2017;
Garcia-Mesa et al. 2017). These cells were derived from immor-
talized primary human microglia and contain a latent reporter
HIV construct that expresses GFP after proviral reactivation.
HC69 cells were treated with pharmacological inhibitors that
target G9a and GLP, two essential members of the CoREST
complex. As shown in Fig. 3b, there was latency-reversing
activity by BIX01294 (22.73% GFP+), which targets G9a/
EHMT2 (Shi et al. 2003) andUNC0638 (26.94%GFP+), which
targets the GLPL/G9a (EHMT1/EHMT2) heterodimer (Vedadi
etal.2011).Bothcompoundsbythemselveswereable toincrease
GFP expression significantly above basal levels (5.3%GFP+).
Todeterminewhether theepigenetic latency-reversing factors
that we identified were specific for microglia, we tested
BIX01294 and UNC0638 on 2D10 cells (Pearson et al. 2008),
a latently infected JurkatTcell line carryinga similarGFP report-
er construct. Neither compound reactivated GFP in these cells
(Fig. 3d), however, both compounds areweak latency-reversing
agents in primary Tcells and patient cells (Nguyen et al. 2017).
We also tested the monoamine oxidase (MAO) inhibitor
phenelzine. Phenelzine was drawn to our attention because,
in addition to it MAO inhibition activity, it has been reported
to inhibit another member of the CoREST complex, LSD1
(KDM1) (Culhane et al. 2010; Sakane et al. 2011). We found
that phenelzine was a moderate latency-reversing agent in
HC69 cells (12.24% GFP+) (Fig. 3b).
To evaluate whether the effect of phenelzine on HIV reacti-
vation was due to its anti-LSD1 (KDM1) activity or its anti-
MAOactivity,we tested a series of highly specificMAO inhib-
itors orLSD-1 (KDM1) inhibitors.M-30, a specific inhibitor of
MAO, reactivated GFP inHC69 cells (23.31%GFP+) while in
contrast, the specific LSD1 (KDM1) inhibitors RN-1, GSK-
LSD1, and SP-2509 had no effect (Fig. 3c). This indicates that
the phenelzine-mediated reactivation of latent HIV is due pri-
marily to its anti-MAO activity, possibly due to the increased
NF-κB phosphorylation stimulation by phenelzine (Chung
et al. 2012). Thus, MAO inhibition clearly provides a potent
and selective means to reactivate HIV in microglial cells.
Human microglia isolated from HIV-infected humanized
mice can be used to evaluate latency reversal drugs
The latency-reversing agents that are active in the microg-
lia cell line models of HIV latency can potentially be used
Fig. 2 HIV infection of microglia. a Neonate-engrafted humanized mice
were infected with HIV strain JRCSF-HA (n = 6). Virus levels in the
blood were measured over time. Dotted line represents limit of detection
of assay = 1.5 × 103. b After 12 weeks post-infection, glial cells from
individual mice were analyzed by flow cytometry to quantify the frequen-
cy of HIV infection (HA+) in cells expressing markers of human microg-
lia (hCD45+ CD11b+)
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as tools to stimulate HIV production from human microglia
infected in vivo in humanized mice. For an initial study, we
used phenelzine. Although this compound is not as potent
as some of the other MAO inhibitors that we have identi-
fied, it is nonetheless highly selective for microglial cells
and is an FDA-approved antidepressant with proven blood-
brain barrier penetration.
We isolated the total glial cell population from 5 JRCSF-
infected humanized mice and cultured them ex vivo, with or
without phenelzine, for 2 days. HIV released into the super-
natant was measured by qRT-PCR of viral RNA. As shown in
Fig. 3e, there was an approximately twofold increase in the
amount of HIV released from phenelzine-treated cells com-
pared to untreated cells.
Fig. 3 Inhibition of G9a/EHMT2, GLP/EHMT1, or MAO promotes
HIV emergence from latency in microglia. a CHME-5/HIV cells were
subjected to genome-wide shRNA screening to identify shRNAs that
increased HIV (GFP) expression. Members of the CoREST repressor
complex are shown, with the three shRNA target genes with high level
hits indicated (orange). The role of CoREST in latency maintenance was
also confirmed by specific shRNA knockdown (green). Other members
of the complex were analyzed in HC69 cells (see below) using pharma-
cological inhibitors (blue). b HIV emergence from latency in human
microglial HC69 cells, detected by GFP+ expression at 16 h post-
treatment using inhibitors BIX01294 (G9a inhibitor), UNC0638 (GLP/
G9a inhibitor), and phenelzine (LSD1 and MAO inhibitor). In the flow
cytometry plots, GFP+ cell populations are colored green, and the per-
centage of GFP-expressing cells is indicated. c To determine whether
phenelzine activation of HIV latency is due to LSD1 or MAO, HC69
cells were treated with LSD1 inhibitors (phenelzine, RN-1, GSK-LSD1,
or SP-2509) or MAO inhibitors (phenelzine or M-30) and analyzed for
GFP expression. d Activation of HIV from HC69 cells (microglia laten-
cy—black bars), 2D10 cells (T cell latency—red bars), or HA3 cells
(monocytic latency—blue bars), treated with the indicated drugs. Error
bars represent the standard deviation of three or more experiments. eGlial
cells from five individual JRCSF-HA-infected mice were cultured with or
without phenelzine for 2 days, and HIV copies in the culture supernatants
measured by qRT-PCR. Error bars represent standard error of the mean
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An unusual feature of the reversal of HIV latency is that the
induction of Tat leads to an Ball or nothing^ induction of tran-
scription. When latency is reversed, intermediate levels of HIV
expression in those cells are never seen. Therefore, increases in
HIVexpression invariably correlatewith an increase in the num-
ber of cells producingHIV (Jadlowsky et al. 2014;Mbonye and
Karn 2017; Nguyen et al. 2017). Thus, the enhanced viral pro-
duction seen after treatment of the glial cell population with
phenelzine is consistent with reversal of latency in a subset of
the infected microglial cell population (Fig. 3e).
Discussion
HSC-reconstituted mice harbor human microglia in their
brains
Amajor cell type in the CNS that supports productive infection
byHIVis themicroglia, amacrophage-like cell that functions as
the primary immune cell of the brain. To facilitate studies of both
productiveandlatent infectionsofmicroglia thatcouldcontribute
to thepersistenceofHIVin theCNSduringART,wehavebegun
to characterize the human cells present in the brains of HSC-
transplanted,HIV-infectedhumanizedmice.Wereadilydetected
human cellswithmarkers ofmicroglia in these humanizedmice,
based on co-expression of CD11b and the more specific
microglial marker, P2RY12 (Butovsky et al. 2014).
Furthermore, in HIV-infected animals, we detected HIV-
infected cells in this fraction (mean 9% of humanmicroglia).
Despite the macrophage-like properties of microglia, fate-
tracking studieshave shown that theydevelop fromanembryonic
lineage, yolk sac erythro-myeloid progenitors, that are distinct
from HSC, which derive from the aorta-gonad-mesonephros re-
gion (Medvinsky and Dzierzak 1996). Accordingly, it has been
debatedwhetherornotHSCcangiverisepost-natally tomicroglia
(Ginhoux et al. 2013). However, mouse-to-mouse transplant ex-
periments have shown that donorHSCproduce cells that are phe-
notypically indistinguishable frommicroglia in mice whose resi-
dentmicroglia have been depleted by radiation, chemotherapy, or
through microglia-specific expression of a suicide gene
(Capotondo et al. 2012; Derecki et al. 2012; Sergijenko et al.
2013; Varvel et al. 2012). Furthermore, injection of human HSC
into radiation-treated immune-deficient mice populates the brain
with human cells expressing microglial markers (Asheuer et al.
2004).Theseobservationsalso fitwith findings fromclinical trials
using genetically modified autologous HSC to treat neurological
diseases such as ALD, where conditioning allows microglia de-
rived from the engineered HSC to provide enzymatic trans-
complementation and clinical benefit (Cartier et al. 2009).
Our characterization of humanized mice also supports the
idea that transient depletion of endogenous mouse microglia
allows repopulation by human HSC-derived cells.
Conditioning using busulfan, which depletes endogenous
microglia more than irradiation, nearly doubles microglial cell
engraftment in the brains of the mice. This also provides a
simple technical advance that makes the humanized mouse
model a more effective and practical approach to studies of
HIV infection in the brain.
MAO inhibitors specifically reactivate latent HIV
in microglia
Weare currentlyusinghumanizedmice to studywhether latently
infected microglia can persist in mice treated with ART, and to
evaluatewhether any such reservoir could be perturbed by com-
pounds that specifically reactivate latent HIV in microglia. We
have previously reported that distinct pathways are involved in
the activation of latent HIV in microglia, including the TLR3
pathway (Alvarez-Carbonell et al. 2017). We used a shRNA
screen in a cell line model of HIV latency to identify microglia-
specific pathways based on the CoREST repressor complex.
Pharmacological inhibition of key epigenetics-modifying en-
zymes in this complex (EHMT1andEHMT2) led to the specific
reactivation of latent HIV in microglial cells, but not in cell line
models of latent HIV in T cells or monocytes. These results are
consistent with previous reports that EHMT2 is an important
regulator of HIV latency in microglial cell lines (Le Douce et al.
2012;Marban et al. 2007).While phenelzine also acts as a weak
inhibitor of the CoREST complex protein LSD-1 (KDM1), we
found that it is its ability to inhibit MAO that reversed latency in
microglial cells.We then studiedwhether otherMAO inhibitors,
such asM-30, could also reactivate HIVand found that they are
indeedpotentandselectivereactivatingagents inmicroglialcells.
The reactivation of latent HIV by specific drugs is being
considered as an adjunct to ART that could reduce the latent
reservoir through a Bshock and kill^ approach and thereby
allow an HIV cure. Although the major focus in such studies
has been on drugs that can activate latent T cells, latent reser-
voirs in the CNS are likely to become a major barrier to curing
HIV (Brew et al. 2015; Darcis et al. 2017; Katlama et al. 2013;
Siliciano and Siliciano 2013). Phenelzine is FDA-approved as
an antidepressant and has proven blood-brain barrier penetra-
tion. Therefore, phenelzine, along with other MAO inhibitors,
should become useful tools to reverse HIV latency in the
humanized mouse model.
Modeling HIV latency in microglial cells using
HSC-reconstituted humanized mice
We also evaluated the ability of phenelzine to stimulate HIV
production from microglia harvested from HIV-infected hu-
manized mice and found that it was able to increase HIV
production in these cells approximately twofold. In this exper-
iment, the difference in levels of virus released from
unstimulated and phenelzine-stimulated cells was likely min-
imized because the cells used for this experiment were from
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non-ART-treated mice, which increases the background of
HIV production in the untreated cell control. Although we
have not yet formally ruled out that this effect of phenelzine
is due instead to enhanced production of HIV from produc-
tively infected cells, work in cell models has shown that in-
duced cells produce HIV Tat and therefore have a uniformly
maximal induction of HIV transcription. Thus, increases in
HIV production after latency reversal invariably reflect in-
creases in the number of productive cells (Jadlowsky et al.
2014; Kim et al. 2011; Mbonye et al. 2013; Nguyen et al.
2017). The phenelzine data therefore indicates that a subset
of microglia recovered from the reconstituted mice are latently
infected and can be reactivated by this drug.
Going forward, we plan to study the effect of various la-
tency reactivators, including pro-inflammatory molecules and
inhibitors of repressor complexes, on HIV emergence from
latency in microglia harvested from ART-treated animals.
We are also expanding the ex vivo studies using sensitive
intracellular RNA detection methods to more rigorously dem-
onstrate latency in this system.
Modeling HIV-associated neurocognitive disorders
HIV-1 replication in theCNS is probably initiated from invading
monocytes and then spreads to microglial cells and astrocytes
within the brain parenchyma (Churchill et al. 2009; Cosenza
et al. 2002; Fischer-Smith et al. 2004; Liu et al. 2004;
Takahashi et al. 1996; Wiley 2003; Wiley et al. 1986).
Definitive evidence that HIV replicates in macrophages within
theCNScomesfromtheobservationthatHIV-associateddemen-
tia (HAD)patientsharbormacrophage-tropicHIV-1variants that
growselectively in theCNS(Gorryet al. 2002;Peters et al. 2004;
Rossi et al. 2008; Schnell et al. 2011). A consequence of HIV-1
replication in longer-lived cell types in the brain, such as
microglial cells, is that virus in the cerebrospinal fluid (CSF)
decaysmore slowly thanvirus found in theperipheral circulation
after the initiation of therapy (Schnell et al. 2009).
An important contribution to HIV-1 neuropathology is the
combined neurotoxic effects of viral proteins and exaggerated
inflammatory responses. In vitro studies have demonstrated
the toxic effects of the viral proteins gp120 (Kaul and Lipton
2006) and Tat (El-Hage et al. 2011; Li et al. 2009) on neurons.
Both in vitro and in vivo studies have shown that immune-
activated, HIV-infected, brain-infiltrating macrophages, and
resident microglia, also release high levels of neurotoxic cy-
tokines such as TNF-α and IL-1β (Kaul and Lipton 2006).
Cytokine release is also a response to HIV proteins, since
exposure of macrophages to intact HIV-1 virions or gp120
induced IL-1β release independently of productive infection
(Cheung et al. 2008; Herbein et al. 1994; Merrill et al. 1989).
Importantly, neuronal dysfunction does not correlate with
the number of HIV-infected cells or viral antigens in CNS
(Glass et al. 1995; Masliah et al. 1997), but rather with
elevated inflammatory cytokine levels. Elevated TNF-α
mRNA levels in microglia and astrocytes (Glass et al. 1995;
Wesselingh et al. 1997) and high levels of IL-1β and TNF-α
are seen in the CNS of patients with HAD (Brabers and Nottet
2006; Epstein and Gendelman 1993). Similarly, increased IL-
6 and IL-8 levels have also been reported in the brains of HIV-
1 infected patients (Breen et al. 1990), and several studies
show that gp120 also induces IL-6 expression in mixed cul-
tures of human primary brain cells (Yeung et al. 1995) and
murine primary mixed glial cell cultures (Kong et al. 1996). A
central role for IL-6 in gp120-induced neuroinflammation has
been demonstrated using a rat model (Schoeniger-Skinner
et al. 2007), where intrathecal administration of gp120 in-
duced the expression of IL-6, TNF-α, and IL-1β.
It is notable that the inflammatory signals correlated with
HAND in well-suppressed patients are the same signals that in-
duce latent HIV in microglial cell models (Alvarez-Carbonell
et al. 2017). The development of the humanized mouse models
described here offers an exciting opportunity to investigate the
inter-relationship betweenHIV latency and chronic inflammato-
ry on the development of neuropathology in vivo.
Methods
Cell lines Cell lines CHME-5/HIV (microglia), HC69 (mi-
croglia), 2D10 (T cell), and HA3 (monocytic) are models of
HIV latency, containing a GFP reporter in place of gag in an
HIV proviral clone, and expressingGFP only when stimulated
(Alvarez-Carbonell et al. 2017; Garcia-Mesa et al. 2017;
Pearson et al. 2008; Wires et al. 2012). CHME-5/HIV cells
were cultured in DMEM plus 5% FBS (ThermoFisher
Scientific, Carlsbad, CA), HC69 cells in DMEM plus 1%
FBS, 2D10, and HA3 cells in RPMI plus 10% FBS
(ThermoFisher Scientific).
Creation of humanized mice NOD Cg-Prkcdscid
Il2rgtm1Wjl/SzJ (NSG) were conditioned using sub-lethal ra-
diation doses of 150 Gy (neonates) or 250 Gy (adults), or
treated with 35 mg/kg busulfan (adults) (Alpha Aesar,
Haverhill, MA). After 4 h (irradiation) or 24 h (busulfan),
the mice were injected with 1 × 106 CD34+ cells, isolated
from human fetal liver, as previously described (Holt et al.
2010; Wang et al. 2015). Human cell engraftment levels in
the blood were measured in animals from 8 weeks of age
using an antibody mix containing human-specific antibodies:
anti-hCD3-PE (UCHT1) anti-hCD4-FITC (RPA-T4) and anti-
hCD45-PerCP (2D1) (BD Biosciences, San Jose, CA).
HIV-1 virus production and infection of humanized mice
The HIV-1 proviral clone, JRCSF-HA, was generated by
inserting an HA epitope-tagged HSA protein into the vpr open
reading frame of JRCSF (Koyanagi et al. 1987) and is similar
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to the NL4-3-HSA-HA clone previously published (Ali and
Yang 2006). Virus stocks of JRCSF and JRCSF-HA were
generated by transient transfection of HEK 293T cells
(ATCC, Manassas, VA), using 18 μg of plasmid in a 10-cm
plate, essentially as described (Cannon et al. 1994). Virus titer
(infectious units/mL) was determined by infection of
Ghost(3)X4/R5 cells, obtained through the NIH AIDS
Reagent Program, Division of AIDS, NIAID, NIH, from
Drs. Vineet N. Kewalramani and Dan R. Littman (Morner
et al. 1999), as previously described (Cecilia et al. 1998).
Humanized mice between ages 12 to 20weeks, engrafted with
at least 30% human CD45+ cells in the blood, of which at least
10% were CD3+/CD4+, were infected with JRCSF or
JRCSF-HA, using 500 μL intraperitoneal injections contain-
ing 5 to 10 × 105 infectious units.
HIV-1 qRT-PCR HIV-1 RNAwas extracted fromeither 50μL
of mouse blood, or 100 μL cell culture supernatants, using a
QiagenViral RNA IsolationKit according to themanufacturer’s
instructions (Qiagen, Hilden, Germany). qRT PCR was per-
formed using the Taqman RNA-to-CT One Step Kit, according
to the manufacturer’s instructions (Applied Biosystems, Foster
City,CA).PrimersusedwereLTR-F:5′-GCCTCAATAAAGCT
TGCCTTGAG-3′ and LTR-R: 5′-GGCGCCACTGCTAG
AGATTTTC-3′, with a FAM-TAM probe sequence: 5′-AAGT
AGTGTGTGCCCGTCTGTTRTKTGACT-3′ (Applied
Biosystems). Cycling conditions used were 1 cycle of 45 °C for
35min, then 43 cycles of 95 and 68 °C for 1min each. Standards
were 10-fold dilutions of an in-house titered NL4-3 virus stock.
Limit of detection (LOD) of the assay is 10 copies, which corre-
sponds to 1500 copies/mL mouse blood or 500 copies/mL cell
culture supernatant.
Glial cell isolation and flow cytometry Mice were anesthe-
tized with avertin and cardiac perfused with 30–50mL PBS to
remove lymphocytes and macrophages from the brain. Glial
cells were isolated essentially as described (Moussaud and
Draheim 2010). Briefly, brains were minced and
collagenase/dispase (Roche, Basil, Switzerland) treated for
30 min at 37 °C and then DNAse treated (Roche). Cells were
washed with PBS and resuspended in 20% isotonic Percoll (in
Hank’s balanced saline solution (HBSS) (ThermoFisher
Scientific), with HBSS layered on top, and centrifuged for
20 min at 200 g. The interphase containing myelinated cells
was discarded and the pelleted fraction (glial cells) washed
with HBSS and immunostained with anti-human CD45-
PerCP (2D1) (BD Biosciences), anti-CD11b-PE (M1/70)
(Biolegend, San Diego, CA) and anti-P2RY12 (Abcam,
Cambridge, United Kingdom). For P2RY12 (unconjugated),
donkey anti-rabbit Alexa Fluor 488 (ThermoFisher Scientific)
was used as a secondary antibody. Flow cytometry analyses
were performed using a FACSCanto II (BDBiosciences), with
compensation samples created using BD CompBeads (BD
Biosciences). Data were analyzed using FlowJo software
V7.6.5 (Treestar, Ashland, OR).
Unbiased human shRNA screening CHME-5/HIV cells
weresubjectedtogenome-wideshRNAscreeningusingahuman
shRNA library packaged in VSV-G pseudotyped lentiviral vec-
tors (Cellecta Inc., Mountain View, CA). The lentiviral library
comprises 82,500 shRNAs targeting 15,439 mRNA sequences
and carries a puromycin-resistance cassette. Transduced cells
were selected in puromycin (2 μg/mL), and GFP-positive cells,
which indicateHIVreactivation, selected byFACS. Puromycin-
resistant/GFP+cellswereexpandedto1 × 107cellsandsubjected
toanadditional tworoundsofGFP+sorting.After the third round
of purification/expansion, when nearly 50% of the cells were
constitutively GFP+, genomic DNAwas isolated from 4 × 106
cells and used as a template for nested PCR using primers that
recognize sequences flanking the unique bar-code sequences in
the lentiviral vectors, and which are unique for each shRNA.
High throughput deep sequencing was performed on the nested
PCR-amplified product and the sequenced bar-codes de-convo-
luted to their shRNA sequences using the Decipher
Deconvolution software (Cellecta Inc.). The shRNAswere then
ranked based on their abundance, and classified by Ingenuity
PathwayAnalysis™.
Transduction of CHME-5/HIV cells with specific shRNA
vectors 105 CHME-5/HIV cells were transduced with VSV-
G-pseudotyped lentiviral vectors expressing scrambled or
CoREST specific shRNAs. The shRNAs were inserted in the
pLKO.1 backbone and comprised the scrambled non-
silencing GIPZ lentiviral shRNAmir control and CoREST
shRNA RHS4533-NM_015156, obtained from Thermo
Scientific Open Biosystems. Three days after transduction,
drug-resistant cells were selected in medium containing puro-
mycin (2 μg/mL) for at least 7 days. Cell viability and GFP
expression were assessed by FACS and fluorescence micros-
copy, as described below.
Analysis of HIV reactivation in latently infected cell lines
Quantification of GFP expression was performed by flow cy-
tometry analysis using a LSR Fortessa instrument, the
FACSDiva software (BD, NJ) for data collection, and the
WinList 3D software for data analysis. Prior to analysis,
CHME-5/HIV and HC69 cells (adherent) were trypsinized,
collected, and resuspended in 300 μL of cold PBS, while the
suspension cells 2D10 and HA3 were centrifuged, and pellets
resuspended in 300 μL of PBS. Drug treatments of HIV-
latently infected CHME-5/HIV, HC69, HA3, and 2D10 cells
were typical for 16 h, with the following concentrations: 4 μM
BIX01294 (Sigma-Aldrich B9311), 3 μMUNC0638 (Sigma-
Aldrich U4885), 500 μM phenelzine (Sigma-Aldrich P6777),
100 μM M-30 (Sigma-Aldrich SML0128), 100 μM RN-1
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(Tocris 4977), 100 μM GSK-LSD1 (Sigma-Aldrich
SML1072), and 2 μM SP-2509 (Cayman Chemical 15487).
Ex vivo activation of HIV in glial cell fraction Glial cells
(5 × 105) isolated from HIV-infected humanized mice were cul-
tured in DMEM-F/12 (ThermoFisher Scientific), 10% FBS and
penicillin/streptomycin, with or without 5 μM phenelzine
(Sigma).After 2 days,HIVwasquantified from the supernatants
via RNA extraction and qRT-PCR, as described above.
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